DivestmentAug 6, 2026, 08:11 AM
Edgewise Completes $2.65B Muscular Dystrophy Business Sale
AI Summary
Edgewise Therapeutics completed the sale of its muscular dystrophy business and sevasemten to Servier for up to $2.65 billion, including $1.55 billion upfront, significantly strengthening its balance sheet and sharpening its focus on cardiovascular diseases. The company also announced positive top-line data from the Phase 2 CIRRUS-HCM trial for EDG-7500 and plans to initiate a Phase 3 trial in Q4 2026. For the second quarter of 2026, Edgewise reported a net loss of $57.3 million ($0.53 per share), with increased R&D and G&A expenses.
Key Highlights
- Completed sale of muscular dystrophy business and sevasemten to Servier for up to $2.65 billion.
- Received $1.55 billion in upfront cash consideration in July 2026 from the sale.
- Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial for EDG-7500.
- Expects to initiate a Phase 3 trial for EDG-7500 in Q4 2026.
- Reported a net loss of $57.3 million ($0.53 per share) for Q2 2026.
- Research and development expenses increased to $47.5 million in Q2 2026.
- General and administrative expenses increased to $14.4 million in Q2 2026.
- Pro forma cash, cash equivalents, and marketable securities of $2,010.7 million after the sale.
Price Impact
More from EWTX